No price history available.
Key financial summary
Financials in PLN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | PLNm | 1,834 | 1,727 | 543 | 469 | 543 | 574 | N/A | N/A |
| Operating profit | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | PLNm | 930 | 447 | -190 | -20 | 51 | 29 | N/A | N/A |
| EPS reported | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in PLN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Mercator Medical S.A., operating with its subsidiaries, is a key player in the manufacturing and international supply of essential disposable medical provisions. Their primary offerings encompass a broad spectrum of medical gloves, including surgical, protective, sterile examination, and household types, alongside various wound dressings and products made from non-woven fabrics. The company's extensive inventory also features a comprehensive range of single-use apparel like caps, face masks, surgical gowns, shoe covers, staff shirts, sleeve protectors, and patient gowns. Furthermore, Mercator Medical provides specialized surgical items such as drape sheets, unique sterile drapes with non-adhesive openings, complete surgical kits, and a variety of accessories like apparatus and table covers, limb protectors, camera covers, adhesive instrument pockets, and self-adhesive nonwoven tapes. These products are sold under a strong collection of brands, including nitrylex, opero, MERCATOR, Ansell, dermagel, santex, comfort, vinylex, iNtouch, ambulance, and ideal. Their customer base is diverse, spanning medical clients such as healthcare facilities, industrial settings requiring medical supplies, retail chains, and pharmaceutical wholesalers, as well as a wide array of other sectors including beauty, hospitality (hotels, restaurants, catering), cleaning services, agri-food, automotive, home and garden, education, and general retail. Established in 1989, Mercator Medical S.A. is based in Kraków, Poland, and functions as a subsidiary of Anabaza RAIF V.C.I.C. Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Mercator Medical S.A., operating with its subsidiaries, is a key player in the manufacturing and international supply of essential disposable medical provisions. Their primary offerings encompass a broad spectrum of medical gloves, including surgical, protective, sterile examination, and household types, alongside various wound dressings and products made from non-woven fabrics. The company's extensive inventory also features a comprehensive range of single-use apparel like caps, face masks, surgical gowns, shoe covers, staff shirts, sleeve protectors, and patient gowns. Furthermore, Mercator Medical provides specialized surgical items such as drape sheets, unique sterile drapes with non-adhesive openings, complete surgical kits, and a variety of accessories like apparatus and table covers, limb protectors, camera covers, adhesive instrument pockets, and self-adhesive nonwoven tapes. These products are sold under a strong collection of brands, including nitrylex, opero, MERCATOR, Ansell, dermagel, santex, comfort, vinylex, iNtouch, ambulance, and ideal. Their customer base is diverse, spanning medical clients such as healthcare facilities, industrial settings requiring medical supplies, retail chains, and pharmaceutical wholesalers, as well as a wide array of other sectors including beauty, hospitality (hotels, restaurants, catering), cleaning services, agri-food, automotive, home and garden, education, and general retail. Established in 1989, Mercator Medical S.A. is based in Kraków, Poland, and functions as a subsidiary of Anabaza RAIF V.C.I.C. Ltd.
